STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Diamyd Medical AB (STO:DIAMB) (NASDAQ:DMYDY):
Diamyd Medical announced today that the statistically significant protective effect of the experimental Diamyd® vaccine on insulin secretion in type 1 diabetes patients remains still 21 months after the first injection.
